Literature DB >> 12746170

The role of fibroblast transdifferentiation in lung epithelial cell proliferation, differentiation, and repair in vitro.

J S Torday1, E Torres, V K Rehan.   

Abstract

Parathyroid hormone-related protein (PTHrP) expression is necessary for differentiation of mesenchymal lipofibroblasts, which induce epithelial type II (TII) cell differentiation, both of which are necessary for alveolarization. PTHrP deficiency may be associated with bronchopulmonary dysplasia (BPD), characterized by truncation of alveolarization among preterm infants. This is supported by the baboon model of BPD (failure of alveolarization) that manifests PTHrP deficiency. We provide evidence that TII cell PTHrP expression is downregulated by alveolar overdistension, resulting in the transdifferentiation of lipofibroblasts to myofibroblasts, characterized by progressive loss of PTHrP receptor expression and triglyceride content, and sequential upregulation of alpha-smooth muscle actin (alphaSMA), typifying fibrosis. PTHrP reverses the downregulation of the PTHrP receptor and upregulation of alphaSMA, reverting myofibroblasts to a lipofibroblast genotype. When TII cells are co-cultured with lipofibroblasts, they proliferate and differentiate, expressing surfactant protein-B; in contrast, TII cells co-cultured with myofibroblasts fail to develop, mimicking the failed alveolarization associated with BPD. Treatment of myofibroblasts with 15-deoxy-Delta 12, 14 prostaglandinJ(2) (PGJ(2)) stimulates ADRP expression, reconstituting the lipofibroblast phenotype. PGJ(2)-treated myofibroblasts promote TII cell growth and surfactant protein-B expression, indicating that failed alveolarization due to transdifferentiation is reversible. We conclude that alveolar overdistension can cause fibroblast transdifferentiation, resulting in failed alveolarization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12746170     DOI: 10.1080/pdp.22.3.189.207

Source DB:  PubMed          Journal:  Pediatr Pathol Mol Med        ISSN: 1522-7952


  66 in total

1.  Postnatal rosiglitazone administration to neonatal rat pups does not alter the young adult metabolic phenotype.

Authors:  Nghia C Truong; Afshan Abbasi; Reiko Sakurai; W N Paul Lee; John S Torday; Virender K Rehan
Journal:  Neonatology       Date:  2011-11-10       Impact factor: 4.035

2.  Antenatally administered PPAR-gamma agonist rosiglitazone prevents hyperoxia-induced neonatal rat lung injury.

Authors:  Virender K Rehan; Reiko Sakurai; Julia Corral; Melissa Krebs; Basil Ibe; Kaori Ihida-Stansbury; John S Torday
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-08-20       Impact factor: 5.464

3.  On the evolution of development.

Authors:  John S Torday
Journal:  Trends Dev Biol       Date:  2014

4.  Perinatal nicotine exposure suppresses PPARγ epigenetically in lung alveolar interstitial fibroblasts.

Authors:  M Gong; J Liu; R Sakurai; A Corre; S Anthony; V K Rehan
Journal:  Mol Genet Metab       Date:  2015-01-29       Impact factor: 4.797

5.  The ErbB4 receptor in fetal rat lung fibroblasts and epithelial type II cells.

Authors:  Washa Liu; Katja Zscheppang; Sandy Murray; Heber C Nielsen; Christiane E L Dammann
Journal:  Biochim Biophys Acta       Date:  2007-05-05

Review 6.  Prevention and treatment of bronchopulmonary dysplasia: contemporary status and future outlook.

Authors:  Laura Cerny; John S Torday; Virender K Rehan
Journal:  Lung       Date:  2008-01-30       Impact factor: 2.584

Review 7.  Lung evolution as a cipher for physiology.

Authors:  J S Torday; V K Rehan
Journal:  Physiol Genomics       Date:  2009-04-14       Impact factor: 3.107

8.  Reprogramming somatic cells to their embryonic state.

Authors:  Valerie Horsley; Elaine Fuchs
Journal:  HFSP J       Date:  2007-07-27

9.  A central theory of biology.

Authors:  John S Torday
Journal:  Med Hypotheses       Date:  2015-04-04       Impact factor: 1.538

10.  Exploiting cellular-developmental evolution as the scientific basis for preventive medicine.

Authors:  J S Torday; V K Rehan
Journal:  Med Hypotheses       Date:  2009-01-14       Impact factor: 1.538

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.